Purpose: Manganese (Mn) is an effective contrast agent and biologically active metal, which has been widely used for Mnenhanced MRI (MEMRI). The purpose of this study was to develop and test a Mn binding protein for use as a genetic reporter for MEMRI. Methods: The bacterial Mn-binding protein, MntR was identified as a candidate reporter protein.
INTRODUCTION
Manganese (Mn) has been used extensively as a contrast agent in MRI, with an expanding range of applications (1) . In most cases, Mn-enhanced MRI (MEMRI) has relied on endogenous mechanisms of cellular Mn uptake and retention to generate tissue-specific contrast in vivo. Previous reports have shown the utility of MEMRI for imaging neural activity, by means of uptake of Mn through voltage-gated calcium channels (2, 3) , and for in vivo tract tracing, by means of microtubule-mediated transport of Mn along axons and across synapses (4, 5) . We recently presented a genetic method to engineer Mn uptake in cells through the expression of the divalent metal transporter, DMT1 (6) . Currently most MEMRI methods, including the use of DMT1 as a reporter protein, focus on delivery and uptake of Mn to cells and tissues, relying on endogenous methods of Mn retention and transport in the cells of interest. The details of cellular Mn trafficking and metabolism after uptake are not well understood, and only a few mechanisms have been elucidated (7) (8) (9) . In this study, we explored retention of Mn as a platform to further engineer contrast for a MEMRI reporter system, and to better understand the underlying mechanisms of subcellular Mn trafficking.
Given the past successes of MEMRI, retaining Mn within cells of interest with a Mn-binding protein is a logical strategy for a genetically encoded MRI contrast agent. Chelates of paramagnetic metals, usually gadolinium, are the most common contrast agents for clinical MRI (10) and serve as a model for engineering a biological equivalent. Attaching gadolinium or other paramagnetic atoms to a chemical chelator reduces the toxicity of a heavy metal ion, can improve relaxivity, and provides a scaffold for engineering functionality for imaging studies. In metal chelate-based T1-shortening contrast agents, a critical feature is the exposure of the paramagnetic metal to the surrounding solvent, or spin lattice, allowing the ready exchange of water protons. Sequestration of the paramagnetic metal demonstrably reduces proton exchange to quench T1 effects, a phenomenon that has been used to great advantage for designing MRI sensor molecules and enzymatically activated contrast agents (11, 12) Biological chelators of metal ions are abundant as structural or reactive elements in proteins. Although less common than calcium (Ca) or iron (Fe), Mn is an essential cofactor for many enzymes such as arginase I (13), prolidase (14) , and superoxide dismutase (15) . Structural analysis reveals that Mn binding motifs are often deep within these proteins, away from solvent. Having a sequestered metal chelate is not unusual for an enzyme reaction center, but does not allow for ready exchange of water and would minimize the ability of Mn to transfer energy to the spin lattice and lower the T1 effect. Other proteins such as glycosyltransferases bind Mn in a much more open conformation, but these enzymes have a poor selectivity for the metal (16, 17) . The metalloregulatory protein MntR, originally identified in the bacteria B. subtilis, has high selectivity to Mn while leaving the chelated metal exposed to the spin lattice (18, 19) . Like all cells, B. subtilis requires Mn as a trace element and cofactor, while excessive Mn can be toxic to cells, as it can readily interact with iron (Fe) or calcium (Ca) binding sites. To maintain homeostatic levels of Mn within the cell, the bacteria must have a means of sensing Mn, and MntR serves this role (3) . Mn binding in MntR results in a protein conformation, which binds DNA and acts as a repressor of metal transport proteins phylogenetically related to DMT1 (20, 21) . The 17 kD protein binds Mn in two adjacent sites with affinities (K d ) ranging from 0.2-13 mM (19). Moreover, MntR binds Mn with high specificity; physiological levels of Fe or Ca are not competitive for binding. Only cadmium (Cd), which is extremely rare in vivo, has a similar affinity for the protein.
Simply finding a chelator of Mn is clearly not sufficient, as a previous chemical sensor with picomolar affinity for Mn has failed to detect Mn under basal physiological conditions (22) . This points to broader considerations of Mn biology occurring at the subcellular level. Subcellular imaging studies have shown, at a basal state, that Mn is sparse in the cytoplasm and localized in specific organelles, including the nucleus, mitochondrion, and the secretory pathway (23) . Early studies with reconstituted organelles demonstrated that the Sarcoplasmic/Endoplasmic Reticulum Ca specific (SERCA) pumps could actively transport Mn to the endoplasmic reticulum (ER), albeit at low efficiency, and only at concentrations above 200 mM (24) . A growing body of more recent work now suggests that Mn is actively accumulated elsewhere under in vivo conditions. Correlative imaging with X-ray fluorescence and immunofluorescence suggests it is the Golgi apparatus (GA), adjacent to the ER, that contains the highest levels of Mn, even when cells are supplemented with the metal at levels equivalent to MEMRI doses (25) . This is consistent with the observation that glycosyltransferases, which use Mn as a cofactor despite having a low affinity for the metal, are resident in the GA (8, 26) . Having a high local concentration of Mn is absolutely necessary for the proper function of these enzymes. Further support for the hypothesis that the GA functions as an important storage organelle for Mn has come with the characterization of a Mn specific P-type pump, SPCA1, and biochemical assays for GA specific Mn (9, 27) .
Based on the above criteria, we sought to develop a chelation based contrast agent that would bind Mn in a solvent exposed manner and be localized within the GA where Mn concentrations are expected to be high. In this study we used these specifications as the design basis for a new type of reporter protein based on the chelation of Mn. We began by studying the atomic structures of known Mn binding proteins and identified the bacterial Mn sensor MntR as an excellent candidate based on its specificity for Mn and solvent exposed Mn binding motif (19) . We then targeted the protein to the GA by making a fusion to one of its resident proteins, Cab45. The result is a biological contrast agent that provides robust Mn based signal in cells from hours to days, offering an iterative improvement upon and complement to DMT1.
METHODS

Bacterial MntR Expression
MntR in an inducible pET17b vector, previously used in structural studies (NCBI protein databank entry PDB:1ON2), was transformed into chemically competent BL21 bacterial cells (18) . Bacterial cultures (2 mL) were grown overnight in LB media under ampicillin selection and used to inoculate 50 mL cultures of 2XYT media. Cultures were grown to an optical density of 1.0 and isopropyl b-D-1-thiogalactopyranoside (IPTG) was added to 1 mM to induce MntR expression. Cultures were grown for an additional 2 h, after which 1-mL aliquots were removed from each culture and centrifuged into 1.5-mL tubes. Bacteria were washed in 1 mL phosphate buffered saline (PBS) and fixed for 15 min in cold paraformaldehyde (PFA). The bacterial pellets were then transferred to NMR tubes for MRI and relaxometry.
Constructs and Stable Cell Lines
A mammalian expression optimized version of the MntR gene was synthesized (Biobasic Inc.). The original sequence was run through an algorithm that reassigned the codons most compatible for mouse tRNAs and for the most stable mRNA. A Myc tag was introduced to the C-terminus of the protein. The reengineered gene was then put into the pIRES-eGFP expression vector and pCDNA3.1 for transient transfection, and into a retroviral construct to generate stable cell lines. Retroviral MntR stable cell lines were generated using previously described methods (6), using a CMV promoter driving coexpression (by means of an IRES) of both MntR and eGFP. An ER targeted version of MntR was generated by fusion to known targeting signals. The Nterminal signal sequence and C-terminal KDEL ER retention sequence were derived from the ER chaperone protein BiP and fused to MntR using synthetic PCR with long oligonucleotides of the targeting sequences. A Golgi targeted version of MntR was generated by fusion to the full length Golgi native protein Cab45. The whole mCherry-Cab45 gene was synthesized and included convenient sites for fusion of the Cab45 element into MntR (
, denoted as MntR*) using restriction site cloning. For in vivo expression of both MntR* and DMT1, the two proteins cloned into a single fusion transcript with a T2A peptide linker, allowing for multicistronic translation from a single open reading frame (28) . GFP was still expressed by means of an IRES to avoid interactions with the C-terminal KDEL with the final construct consisting of DMT1 T2A MntR*-IRES-eGFP. Transfections of all MntR chimeras with IRES-eGFP and the combined DMT1
T2A MntR*-IRES-eGFP construct were grown for 7 days in HEK293T cells and sorted using flow cytometry for cells with >10 3 log units of eGFP fluorescence. For stable B16 melanoma cells both constructs were placed under neomycin selection for 7 days before sorting for cells with >10 2.5 log units of eGFP signal.
Cell Staining
All MntR chimeras were transiently transfected using a chemical transfection reagent (Mirus Bio) into HEK293T growing on glass slides. Cells were fixed with PFA and immunocytochemistry was conducted using and antiMyc antibody for the integrated Myc tag into MntR (1:500 Abcam), anti-Calnexin as an ER-marker (1:500 Abcam) and anti-58K as a GA marker (1:500 Abcam). Fluorescent Red, Green, and Blue secondary antibodies were used to co-label all markers in each cell. Immunolabeled cells were imaged using an epifluorescence microscope (Leica MZ16F).
MRI of Cell Lines
Relaxometry was performed as previously described (6) . Briefly, cells were supplemented with MnCl 2 (100-300 mM) for 1 h, washed with PBS, trypsinized and gently pelleted for imaging. Cell pellets were imaged on a 7 Tesla (T) Bruker Biospec system, using a T1-weighted two-dimensional (2D) multislice gradient echo (2DGE) sequence (echo time, TE ¼ 3.1 ms; repetition time, TR ¼ 100 ms; flip angle, FA ¼ 45 ) and a 2D multi-slice spin echo (2DSE) saturation recovery sequence (TE ¼ 11 ms; TR ¼ 190 ms, 500 ms, 900 ms, 1.5 s, 3 s), both with in-plane resolution of 100 Â 100 mm 2 and 500 mm slice thickness. 2DSE images with increasing TR values were used to calculate a T1 map using the MRI Analysis Calculator Plugin for ImageJ. Data were plotted as R1(¼1/ T1) (mean 6 standard deviation).
In Vivo MRI of B16 Melanoma Models
All mice were maintained under protocols approved by the Institutional Animal Care and Use Committee at NYU School of Medicine. Melanomas were generated by injecting 10 6 B16 melanoma cells subcutaneously into both flanks of C57Bl/6 adult mice and grown in vivo for 9-10 days before imaging.
Mice were imaged on a 7T Bruker Avance II Biospec system (Paravision 4), using a T1-weighted 2DGE sequence (TE/TR ¼ 3.1/50 ms; FA ¼ 45 ; in-plane resolution ¼ 100 Â 100 mm 2 ; slice thickness ¼ 500 mm) Mice with tumors were given an IP injection of an aqueous solution of MnCl 2 (80 mg/kg) and imaged 3 h and 6 h postinjection. All mice were anaesthetized with $1.5% isofluorane in air during MRI and maintained at 37 C with warm air.
Data analysis was carried out on cross sectional images including both tumors of the dual tumor models. Regions of interest were selected of whole tumors despite heterogeneity to avoid bias, however, tumors with large hypointense regions, indicative of necrosis, were considered artifacts and excluded from the study.
Statistical Analysis.
MRI contrast was computed as:
The control region in all cases was the contralateral wild-type B16 tumor. Contrast values were expressed as a percentage difference. Significance was determined with a two-tailed Student's t-test (P < 0.05), and all variation was expressed as the standard deviation from the mean value.
RESULTS
MntR Was Identified as a Candidate Mn-binding Reporter Protein for MRI.
Initial MRI experiments with MntR were performed using an existing bacterial expression construct (18) . Bacterial cells with induced expression of MntR showed a 110% change in R1 compared with naive bacteria, without any additional supplementation of Mn to the media beyond the trace (low mM) levels essential for growth (Figs. 1a,d ). These data suggested that MntR expression retained Mn in the cell and had potential for use as an MRI reporter in eukaryotic cells. MntR was, therefore, engineered for expression in mammalian cells and transfected transiently into human embryonic kidney (HEK) cells (Figs. 1b,c) Inducing expression of MntR (1MntR) resulted in T1 contrast under standard culture conditions. b: In HEK cells expressing MntR (1MntR), contrast was visually obvious compared with control when cells were fixed and scanned ex vivo. c: In living HEK cells, T1 contrast was indistinguishable from control cells. d: R1 relaxometry showed a significant R1 difference (1MntR versus control) in bacteria (n ¼ 4 for each group) and fixed HEK cells (*P < 0.001; n ¼ 6 1MntR, n ¼ 4 control), but no significant difference in the live HEK cells (P ¼ 0.6; n ¼ 6 1MntR, n ¼ 4 control).
1c,d). Once fixed in PFA and left for several hours, however, visible contrast became apparent in 1MntR cells compared with control (Figs. 1b,d ). Because fixation allows Mn ions to relocate and freely diffuse throughout and even out of the Mn-treated cells, these data suggested that some mechanism in living mammalian cells prevented the binding of Mn to MntR, such as active sequestration of Mn away from the cytosol where the ectopically expressed MntR protein was localized.
MntR Can Be Effectively Targeted to Cellular Organelles
Previous reports have demonstrated that cellular Mn is actively transported into the GA by Ca-and Mn-specific ATP2C pumps (9, 25) . We explored the possible role MntR localization could have by generating chimeras of MntR with other proteins or domains that target the ER and the GA (Fig. 2a) . The ER targeted MntR was a fusion with an N-terminal signal sequence and a C-terminal KDEL peptide sequence from the ER chaperone protein BiP (29) . These domains have been identified as the means of initially translating the protein into the rough ER, by means of the signal sequence, and returning it there from the cis-Golgi, by means of the KDEL sequence; they are otherwise not functional components of BiP. To our knowledge, there is no known peptide sequence tag that can be used to localize a soluble protein to the interior of the GA. Targeting MntR to the GA was therefore achieved by generating a 60 kD fusion to a soluble Golgi resident protein, Cab45 (30) . The whole protein sequence was used, as it is unknown what domain retains Cab45 to the GA. Unlike the ER, the GA is a multicompartment organelle, meaning that any given Golgi protein will not necessarily be ubiquitous throughout every part of the organelle. The ATP2C pumps are less common in the trans-Golgi network (27) , making Mn less abundant for the targeted MntR. The chimera could potentially diffuse into secretory vesicles and get secreted from the cell. Therefore a double chimera was also made, using the Cab45-MntR fusion protein together with the KDEL sequence, in an attempt to restrict the protein to the cis-Golgi where the KDEL receptor actively loads proteins with the KDEL sequence into COP1 vesicles for recycling back to the ER (31).
Expression of nonchimerical MntR was cytoplasmic, much like that of untargeted GFP in the cell (Fig. 2b) , referred to as MntR* (Fig. 2b) . Immunocytochemistry did not reveal an obvious difference between the distribution of Cab45 MntR and MntR* within the GA, but differences in the relative amounts of tagged protein in sub-Golgi compartments would not be detectable using immunocytochemistry.
Targeting MntR to Specific Organelles Generated Differences in T1-Relaxation
Each cell line was assayed by supplementing for 1 h with 300 mM MnCl 2 to approximate a typical Mn dose in MEMRI (32) . Without Mn-supplementation, no R1 differences were apparent, similar to previous work with the DMT1 reporter (6) . Expression of unmodified MntR yielded no significant differences in R1 compared with control HEK cells (Fig. 3a) . The ER targeted chimera, SS MntR KDEL , was similarly ineffectual at producing R1 changes (Fig. 3a) . The GA targeted chimeras, however, did produce improvements in R1.
Cab45
MntR fusion alone gave a small, but significant, 11% gain in R1 over control cells. The largest gains came from the MntR* chimera, creating a 30% increase in R1 compared with control and a significant improvement over Cab45 MntR alone. In HEK cells, the þMntR* cell line gave even greater contrast at 300 mM than transient transfection (Figs.  3b,c) , or a 49% increase in R1. Comparison of HEK and 1MntR* cells over varying concentrations of Mn demonstrated the protein's effect on Mn kinetics. At low levels of Mn, the cell lines were not significantly different in R1 (Fig. 3c) ; however, above 200 mM Mn, control HEK cells had an attenuated response to Mn. The curve could be described by Michaelis-Menton kinetics for a saturable system, wherein absorption rates slow as internal concentration of Mn rises. In contrast, the increase in R1 with [Mn] in 1MntR* cells was linear at these concentrations (R 2 ¼ 0.997), suggesting an increased capacity to store Mn before saturation occurs.
MntR* Retains Mn in Cells, and Acts Synergistically with DMT1
Based on the data suggesting that MntR improves Mn retention in cells, we moved from HEK cells into a model previously demonstrated to have poor Mn retention both in vitro and in vivo (6) . Specifically, B16 melanoma cells lose their R1 gains very quickly after Mn supplementation (Fig. 4) (6) , and therefore provided an excellent model to test MntR. Stable cell lines were generated from B16 cells (1MntR*) and from B16 cells which already overexpressed DMT1 (1D1M). Quantitative immunofluorescence showed no significant difference in MntR expression between the two constructs (P ¼ 0.14, n ¼ 8).
Control B16 cells demonstrated a less distinct Mn saturation curve compared with HEK cells (Figs. 3c, 4a ). DMT1-expressing B16 cells (1DMT1) gave consistently higher R1 values, although the saturation effect was still apparent. R1 values for supplemented B16 and 1DMT1 cells were similar to previously reported values, with a maximal R1 shift of 55% (Fig. 4a) (6) . Compared with the control HEK cells, 1MntR* cells again yielded a linear response to Mn supplementation resulting in a large increase in R1 at high supplementations with a maximal 38% gain, approaching 1DMT1 gains. 1D1M cells gave the largest increase in R1, with overall R1 gains greater than the sum of each components effect (Fig. 4a) . At the lowest level of supplementation (100 mM), the R1 values for the 1D1M cells was greater than that for either 1DMT1 or 1MntR* alone at 300 mM. This resulted in a 166% gain in R1 at 100 mM and 96% at 300 mM, comparing 1D1M with control B16 cells. This enhancement was far greater than the cumulative effect of either DMT1 or MntR* alone and suggests that improving both Mn uptake (DMT1) and retention (MntR*) can act synergistically to enhance R1 in the cell. At the highest levels of supplementation however, dual expression of DMT1 and MntR* was only cumulative at best. Comparing the saturation curves, both the 1DMT1 and 1D1M cell lines are nearing saturation at 300 mM Mn, suggesting diminishing returns at high levels of supplementation.
The advantages of MntR* became more apparent after Mn had been washed from the B16 cells. In a time course study cells were supplemented with 300 mM Mn then washed and incubated in fresh, unsupplemented, media for up to 48 h (Fig. 4b) . Control B16 cells and 1DMT1 cells lost almost all of their Mn based R1 increases within 2 h of supplementation, similar to previous reported data (6). For both 1MntR* and 1D1M B16 cells, the post Mn washout kinetics were more complex. These cell lines did not begin to lose their R1 gains for 2 h after removal of Mn, and retained a significantly higher R1 than control cell lines up to 24 h after supplementation, showing a 96% increase in R1 at 12 h post supplementation. 1D1M lines again gave a synergistic effect showing significant increases in R1 up to 48 h after supplementation with 216% R1 gains at 12 h. Both 1MntR* and the 1D1M lines gave a similar R1 profile overall with a bimodal release of Mn over time.
MntR* Creates In Vivo Contrast in a Tumor Model
B16 melanoma cells are tumorigenic in C57Bl/6 mice, making a ready transition from in vitro cell characterization to in vivo expression of MntR*. We chose this cell line based on previous work with DMT1, wherein it was the weakest example of in vivo contrast with a very narrow window after Mn-supplementation in which contrast was significant (6) . Based on the in vitro cell results described above, the expression of MntR* could potentially produce lasting contrast in vivo where DMT1 could not. In our cell based assays we examined dual DMT1 and MntR* expression in double transfected stable expressing cells. This would be an impractical strategy for in vivo expression; therefore, we made a single multicistronic construct that expressed DMT1, MntR*, and eGFP, which could be readily used for future in vivo studies, to generate additional 1D1M B16 cell lines. We then conducted a longitudinal comparison of control, 1MntR* and 1D1M B16 melanoma tumors, using a dual flank tumor model imaged with MEMRI.
Both 1MntR* and 1D1M tumors were brighter than control B16 tumors and adjacent normal tissues in T1-weighted images acquired 3 h after Mn administration (Figs. 5a,b) , similar to 1DMT1 B16 tumors reported previously (6) . Unlike the previous measurements in þDMT1 B16 tumors (6), both þMntR* and þD1M tumors retained significant and visually obvious contrast at 6 h post Mn administration, compared with control B16 tumors (Figs. 5a-c; *P < 0.01, n ¼ 5 for each comparison). At the 6 h time-point, dual expression of DMT1 and MntR* in the þD1M tumors retained slightly higher contrast, compared with þMntR* tumors, although the difference was not statistically significant (P ¼ 0.1, n ¼ 5). These results were largely consistent with the in vitro experiments, demonstrating that MntR can potentially function better as a reporter than DMT1 after Mn administration in some cell types. The similar in vivo results for the 1MntR* and the 1D1M B16 tumors likely shows how Mn pharmacokinetics may favor engineered retention over uptake for some cell types.
DISCUSSION
The results of this study demonstrate that MntR has potential for application as an MRI reporter protein, but only when expressed within the GA, the subcellular organelle where Mn is concentrated. MntR was chosen as a candidate reporter based on its high affinity to Mn and its atomic structure, in which the Mn-binding motif leaves Mn exposed to interact with the spin lattice (19), a requirement for any T1-agent. However, MntR binds Mn reversibly, taking shape only when enough ambient Mn is present (21) , and making subcellular localization of MntR critical for reporter function. This increases the complexity of design of Mn and other paramagnetic metal-binding proteins as expressible MRI contrast agents, making it imperative to understand not only their chelation properties, but also the underlying biology of metal transport, storage and release within the expressing cells.
Our initial results clearly showed the capacity of MntR as a Mn chelator, but significant additional engineering was required to demonstrate utility as an expressible contrast agent for MRI. Specifically, MntR* was optimized for expression in mammalian cells, and targeted to the cis-Golgi, the region of the GA adjacent to the ER where Mn is most enriched. The data suggests MntR* augments the endogenous biology to hold Mn in the cell longer than normal, but not indefinitely. This is best described by mass action kinetics where, in the cell, Mn should exist partly as free ionic Mn and partly bound to proteins at a wide range of affinities. Expression of MntR* expands the buffered pool of Mn thereby increasing the overall Mn. By this model, MntR* expression would only increase the saturation point of Mn without changing the rates of uptake and release of free Mn. This can be seen in the concentration curves for both HEK and B16 cells, where the control and þMntR* curves differ only as control cells reach saturation (Figs. 3a, 4a) . At the lowest levels of Mn supplementation, there should be no difference in the slope of control versus 1MntR* cells, unlike DMT1 expression, which, by altering the rate of uptake, should increase the initial slope of the line without changing the shape of the curve (Fig. 4a) .
Notably, the T1/R1 changes during Mn washout in B16 melanoma cells expressing MntR* showed two modes of Mn release, one occurring on a fast time-scale within 5 h, and the other more slowly. The loss rate of free Mn should not be effected by MntR*, and the pool of Mn that is free at equilibrium may leave the cells on the order of seconds to minutes, meaning the release profile is almost entirely from the pool of buffered Mn. There are two likely reasons for a bimodal Mn release profile. At the molecular level, MntR has two binding sites with different affinities for Mn, 0.2-2 mM for the first site and 5-13 mM at the second (33) . The release profile could be due to the two rates of disassociation as Mn is cleared from each binding site, but this would require high cooperativity between the two sites, a property that has not been confirmed. A more likely possibility is that the data shows two modes of egress from the cell. We propose that Mn can exit the Golgi and the cell by means of known Ca transport mechanisms, directly through the cytosol and, much more slowly, by means of the secretory pathway. Given the low selectivity of many Ca transport mechanisms this seems likely; however, their permissivity to Mn has not been shown to date.
Our results also indicate that DMT1 and MntR* can be used in combination, to enhance cell uptake and retention of Mn, respectively. These results were most obvious in cultured cells, in vitro. In vivo, the combined expression of DMT1 and MntR* showed a similar trend, but the results did not achieve statistical significance. This highlights the challenges of developing reporter systems for in vivo applications: a tumor within a living animal is very different from the same tumor cells in culture, and optimizations done in vitro may not translate in vivo. This is not surprising because the B16 cells were chosen specifically because of their enhanced ability to excrete Mn, compared with other cells tested (6) . The rate of Mn delivery to the cells as Mn moves through the vasculature and interstitial space, as well as the gradual reduction of Mn, present a challenge to any sort of kinetic model. We conclude from these results that retention of Mn is potentially as important as Mn uptake for a Mn-based MRI reporter, but the optimal combination of the two can only be determined as more in vivo models are explored with these technologies.
Beyond the goal of creating genetic reporters for MEMRI, the process of engineering MntR into a functional contrast agent has provided key insights into cellular Mn biology and what the contrast created in MEMRI actually shows. Mn is not simply a cellular marker in MEMRI, it is actually functioning, at least in some situations, as a Golgi stain or marker of the secretory pathway. This view greatly illuminates existing studies using MRI tract tracing with Mn, which depends on the Mn traveling anteriogradely along axonal pathways (4, 5) . While the MEMRI community generally accepts that Mn transport is an active process, the data presented here supports a model wherein the movement of Mn along axons is specifically transported by means of components of the Golgi and Golgi-associated vesicles. This is a critical concept as MEMRI moves into reporter gene imaging. Cell types such as Purkinje and granule cells in the cerebellum, or pyramidal neurons in the cortex have distinct layers where their cell bodies are located with extended axons and dendrites forming separate layers (34) . MEMRI signal in these cell types could therefore be found peripheral to the cell bodies within the layers innervated by the axons and dendrites.
MntR and DMT1 represent the first elements of an expanding tool set that can be expressed alone or in combination to maximize Mn-based MRI contrast. The current construct, resulting in DMT1/MntR* coexpression can already be integrated into most viral and transgenic expression systems currently in use. Further refinements such as minimization of the Cab45 targeting component to MntR*, and/or optimization of DMT1/ MntR* expression ratios, will be important for implementation with larger promoters in expression constructs. Advances in these areas could make possible dynamic studies of in vivo gene expression, longitudinal cell fate mapping using Cre or other site specific recombinases (35) , or activity dependent neuronal circuit mapping, for example, using cfos-tTA transgenic approaches (36) . MEMRI has already become an increasingly important method for small animal imaging and with technologies to engineer the uptake and retention of Mn, genetic imaging studies with MEMRI have become a feasible method for exploring biological questions in vivo.
